B and T lymphocyte attenuator marker for use in adoptive T-cell therapy
US9512401B2 · kind B2 · utility
2Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 30, 2011 |
| Grant date | Dec 6, 2016 |
| Priority date | — |
| Expiry date | Aug 31, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/57
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
BTLA-positive (“BTLA+”) lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.